medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 3

<< Back Next >>

Med Int Mex 2010; 26 (3)

Biological drugs in rheumatoid arthritis

Mora ATT, Andrade OL, Bourlon CRA

Language: Spanish
References: 89
Page: 259-268
PDF size: 175.21 Kb.


ABSTRACT

Rheumatoid arthritis is a chronic, systemic, inflammatory disease, with an autoimmune origin, which frequently produces deformation and destruction of joints and is associated to physical disability and psychosocial morbidity. The early and aggressive treatment is decisive to avoid progression and destruction of joints. Biological drugs represent a very effective therapeutic option, with tolerable adverse effects. This group of drugs has demonstrated to reduce inflammation in an important manner, to inhibit radiographic progression and to induce remission. This paper reviews: pharmacokinetics, biological effects and the studies demonstrating efficacy and safety of biological agents indicated as monotherapy and combined treatment.


REFERENCES

  1. James R O´Dell. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-2602.

  2. Kenneth G, Gim Gee, et al. American College of Rheumatology 2008 Recommendations for the use of Nonbiological and Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum 2008;59:6;762-784.

  3. Olsen N. New drug for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.

  4. Sohita D, et al. Etanercept a review of its use in the management of rheumatoid arthritis. Drugs 2007;67(8):1211-1241.

  5. Ulrich K. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46(8): 645-660.

  6. Buch MH. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 2007;46;1153-1156.

  7. Zintzaras E. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008;30(11):1939-1955.

  8. Donahue K, et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-134.

  9. ERA.

  10. Lars Klareskog, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-681.

  11. Désireé van der Heijde, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum 2006;54(4):1063-1074.

  12. Ravinder M, et al. Infliximab (chimeric anti-tumour necrosis factor-monoclonalantibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-1939.

  13. Ferdinand CB, et al. The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1): 26-37.

  14. Bernard C. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21(1):27-42.

  15. Alonso-Ruiz A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.

  16. Daniel T. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244- 279.

  17. Ternant D. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5(1): S37-S47.

  18. Kievit W, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-1478.

  19. Valesini G. Biological and clinical effects of anti-TNFα treatment. Autoimmuni Rev 2007;7:35-41.

  20. Hyrich KL, et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008;47:1000-1005

  21. Combe B, et al. Efficacy, safety, and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomized two-year study. Ann Rheum Dis 2009;68(7):1146-1152.

  22. Boulos H. Etanercept in the treatment of rheumatoid Arthritis. Ther Clin Risk Manag 2007:3(1) 99-105.

  23. Gibofsky A. Combination therapy for rheumatoid arthritis in the era of biologicals. HSS J 2006;2:30-41. 24. StClair WE, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004; 50(11):3432-3443.

  24. Weinblatt ME. Adalimumab, a fully human anti–tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The arthritis rheumatoid trial. Arthritis Rheum 2003;48(1):35-45.

  25. Keystone EC, Kavanaugh A, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNF monoclonal antibody inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [Abstract]. Arthritis Rheum 2002;46.

  26. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic,clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled,52-week trial. Arthritis Rheum 2004;50:1400-1411.

  27. Weinblatt ME, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: arthritis rheumatoid 4 year extended study. Ann Rheum Dis 2006;65:753-759.

  28. Schiff M, et al. Efficacy and safety of abatacept or infliximab vs. placebo in ATTEST: a phase III, multi-centre, randomized, double blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103.

  29. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68(11):1739-1745.

  30. Van der Kooij SM, et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68(7):1153-1158.

  31. Pavelka K et al. Increasing the infliximab dose in rheumatoid arthritis patients : a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68(8):1285-1289.

  32. Masao Nawata. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18:460-464.

  33. Goekoop-Ruiterman YP, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumathoid arthritis (the BeSt Study). Arthritis Rheum 2008;58(2 Suppl):S126-135.

  34. Bruns A. Prospective cohort study of effects of infliximab on rheumatoid factor,anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009;76(3):248-253.

  35. Mark A. Quinn, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 2005;52(1):27-35.

  36. Dixon WG, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54(8):2368-2376.

  37. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20(3):334-339.

  38. Lee SJ. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am 2006;32(1):3-10.

  39. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.

  40. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39(5):327-346.

  41. Emery P, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006;54(5):1390-1400.

  42. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54(9):2793-2806.

  43. Bresnihan B, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204.

  44. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(11):2838-2846.

  45. Cohen SB, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate; results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(3):614-624.

  46. Cohen SB, et al. A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63(9):1062-1068.

  47. Schiff MH, et al. Saftey of combination therapy with Kineret (anakinra) and etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61(suppl. 1):185.

  48. Genovese MC, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419.

  49. Fleischmann RM, et al. Anakinra, a recombinant human interleukin-I receptor antagonist, in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:927-934.

  50. Fleischmann RM, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(8):1006-1012.

  51. Salliot C, et al. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.

  52. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004;26(12):1960-1975.

  53. Kineret (Anakinra) Package inserts. Amgen Inc 2001;p:1-11.

  54. Nadler S, Townsend R, Mikesell G. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations. Ann Rheum Dis 2004;63(suppl 1):142.

  55. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.

  56. Budd RC, Fortner KA. T Lymphocytes. In: Harris ED, Budd RC, Firestein GS, et al. eds. Kelley’s textbook of rheumatology. 7th ed. Philadelphia: Elsevier/Saunders, 2005;p:133-152.

  57. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 4. Art: CD007277. DOI: 10.1002/14651858.CD007277.pub2.

  58. Moreland LW, Alten R, Van den Bosch F, et al. Co stimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-1479.

  59. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915.

  60. Kremer J, Shergy W, Tindall E, et al. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum 2004;50:S182.

  61. Westhovens R, Emery P, Aranda R, et al. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis (RA) patients with inadequate responses to methotrexate (MTX). Ann Rheum Dis 2006;65:S512.

  62. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 2006;144:865-876.

  63. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123.

  64. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic diseasemodifying antirheumatic drugs: a one-year randomized, placebo- controlled study. Arthritis Rheum 2006;54:2807-2816.

  65. Bruce S, Boyce EG. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother. 2007;41(7):1153-1162.

  66. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis (review). Cochrane Database Syst Rev. 2009 Oct 7;(4).

  67. Mihara M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Inmunopharmacol 2005;5:1731-1740.

  68. Mihara M, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 2001;98:319-326.

  69. Matsuno H, et al. Treatment of rheumatoid synovitis with antireshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid tissue implants in the SCID mouse model. Arthritis Rheum 1998;41:2014-2021.

  70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.

  71. Nishimoto N, et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30:1426-1435.

  72. Choy EH, et al. Therapeutic Benefit interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, doseescalation trial. Arthritis Rheum. 2002;46:3143-3150.

  73. Nishimoto N, et al. Treatment of rheumatoid arthritis with humanaized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo controlled trial. Arthritis Rheum. 2004;50:1761-1769.

  74. Nishimoto N, et al. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-391.

  75. Nishimoto N, et al. Blocking interleukin-6 by Tocilizumab (a humanaized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis: evidence from a X-ray reader-blinded randomized controlled trial. Arthritis Rheum 2005;52:4109.

  76. Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-1523.

  77. Smolen JS, et al; Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-997.

  78. Genovese MC, McKay JD, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs:the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-2980.

  79. Jones J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88-96.

  80. Nishimoto N, et al. Study of active controlled monotherapy used for rheumathoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader blinded controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-1167.

  81. Keystone E, Mason D, Fleischmann R. Certolizumab pegol 400 mg every 4 weeks as monotherapy rapidly reduces disease activity in active rheumatoid arthritis. Arthritis Rheum 2007;56(Suppl 9):S156.

  82. Keystone E, Mason D, Combe B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: 1-year results from the RAPID 1 study. Arthritis Rheum. 2007;56(Suppl 9):S300-S301.

  83. Landewe RB, Strand V, Smolen J, et al. Liquid formulation certolizumab pegol with methotrexate decreases progression of structural joint damage in rheumatoid arthritis patients: the RAPID 2 study. Arthritis Rheum 2007;56(Suppl 9):S298-S299.

  84. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, doseranging study. Arthritis Rheum 2008;58(4):964-975.

  85. Genovese M, Kaine J, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58(9):2652-2661.

  86. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial. Arthritis Rheum 2007;56(Suppl 9):S793-S794.

  87. Burge D, Martin R, Wallace D, et al. Safety and pharmacodynamics of repeat administration of TRU-015, a CD20-directed SMIP™ therapeutic, in subjects with rheumatoid arthritis. Arthritis Rheum 2007;56(Suppl 9):S168-S169.

  88. Clifton O. Emerging Therapeutics for rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2008;66(3):210-215.

  89. Baldassare A, Fiechtner J, Filipowicz-Sosnowska A, et al. Preliminary safety and efficacy of LTβR-Ig (BG9924) in the treatment of rheumatoid arthritis (RA). Arthritis Rheum 2007;56(Suppl 9):S394.




2020     |     www.medigraphic.com